NCT00249262View on ClinicalTrials.gov

Taxoprexin Treatment for Advanced Skin Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Metastatic Melanoma
Interventions
DRUG

Taxoprexin

Administered by intravenous infusion over 1 hour infusion weekly for the first five weeks of a six week cycle.

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY

NCT00249262 - Taxoprexin Treatment for Advanced Skin Melanoma | Biotech Hunter | Biotech Hunter